During Monday’s current trade, Nokia Corporation (NYSE:NOK)’s shares declined -0.33% to $7.60.
Nokia is planning to return to the consumer mobile handset market, according to Re/code.
According to a report in Re/code citing two anonymous sources, the Finnish company is exploring a return to the mobile phone making business in 2016, though not in the same vein as when it was the world’s-biggest mobile-phone manufacturer.
After Nokia sold its handset business to Microsoft MSFT +2.41% last year for $7 billion, its licensing business Nokia Technologies was one of a trio of divisions left behind.
The other two units were its mapping and locations business which oversees HERE, and its network equipment business, which just bought France’s Alcatel-Lucent for $16.6 billion.
The resurgent mobile business would not be a straightforward manufacturing venture, but largely involve licensing Nokia’s brand and designs to a vendor like Taiwan-based Foxconn.
Nokia Corporation, together with its auxiliaries, provides network infrastructure and related services in Finland, the United States, Japan, China, India, the Russian Federation, Germany, Taiwan, Indonesia, Italy, and internationally.
During an afternoon trade, Halliburton Company (NYSE:HAL)’s shares climbed 3.39% to $48.49.
Halliburton Company, declared that income from ongoing operations for the first quarter of 2015 was $418 million, or $0.49 per diluted share, not taking into account special items. This compares to income from ongoing operations for the first quarter of 2014 of $623 million, or $0.73 per diluted share. Adjusted operating income was $699 million in the first quarter of 2015, contrast to operating income of $970 million in the first quarter of 2014.
Halliburton’s total revenue in the first quarter of 2015 was $7.1 billion, contrast to $7.3 billion in the first quarter of 2014.
Primarily as a result of the recent downturn in the energy market and its corresponding influence on the company’s business outlook, Halliburton recorded about $823 million, after-tax, or $0.97 per diluted share, in company-wide charges during the first quarter of 2015 related to asset write-offs, inventory write-downs, impairments of intangible assets, severance costs, and other charges. Halliburton also recorded a Venezuela currency devaluation loss of $199 million, or $0.23 per diluted share, and Baker Hughes acquisition-related costs of $35 million, after-tax, or $0.04 per diluted share. Stated loss from ongoing operations was $639 million, or $0.75 per diluted share. Stated operating loss was $548 million for the first quarter of 2015.
Halliburton Company provides a range of services and products to the upstream oil and natural gas industry worldwide. The company operates through two segments, Completion and Production, and Drilling and Evaluation.
Genetic Technologies Limited (NASDAQ:GENE), during its Monday’s current trading session gained 28.48%, to $5.43.
Today, Genetic Technologies Limited, declared that a further two (2) new breast health centres will start to offer BREVAGenplus® to their at-risk patients in a systematic fashion. This is in addition to the six (6) breast health centres that the Company formerly declared were set to adopt BREVAGenplus, of which all six (6) have in fact offered samples during the March 2015 quarter.
With an additional number of new breast health centres predictable to follow suit later in calendar year 2015, the Company reiterates that it anticipates sales growth to accelerate in the second half of calendar 2015 and beyond.
Importantly, the Company believes that the adoption of BREVAGenplus by a total of eight (8) new breast health centres validates the company’s recently re-focused sales and marketing strategy, declared in September 2014, whereby the Company shifted its focus to these large facilities. While these centres are more complex entities with longer sales cycles, they offer higher and more stable long-term revenue potential.
The Company is working closely with these pivotal breast health centers and referring health care practitioners to ensure the creation of a personalized comprehensive breast cancer risk assessment approach in which BREVAGenplus plays an integral role. In this way, the Company aims to reinforce the benefits of the test, ease its adoption by the new clinics and ensure its routine use by them.
Genetic Technologies Limited provides genetic testing services primarily in Australia and the United States. It offers a range of genetic tests for breast and ovarian cancer, bowel and uterine cancer, and prostate cancer; neurogenetic diagnostic assays; and gene testing for Epilepsy SCN1A gene related disorders.
Finally, Facebook, Inc. (NASDAQ:FB), gained 2.66% Monday.
Facebook, was reiterated as Outperform with a $100 price target (as compared to a $80.78 close) at Oppenheimer. The firm anticipates Facebook to beat earnings expectations this week.
On the other hand, Facebook, declared that the company’s first quarter 2015 financial results will be released after market close on Wednesday, April 22, 2015.
Facebook will host a conference call to talk about its results at 2 p.m. PT / 5 p.m. ET the same day.
Facebook, Inc. operates as a social networking company worldwide. It provides a set of development tools and application programming interfaces that enable developers to integrate with Facebook to create mobile and Web applications.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
